MN709

MN709 (also known as MN-709) is a small molecule phosphodiesterase 4 (PDE4) inhibitor that was originally developed by Kyorin Pharmaceutical and later licensed by MediciNova for the treatment of inflammatory respiratory diseases, specifically asthma. As a PDE4 inhibitor, MN709 works by preventing the breakdown of cyclic adenosine monophosphate (cAMP) in inflammatory cells and airway smooth muscle. The resulting increase in intracellular cAMP levels leads to the suppression of pro-inflammatory cytokine release and promotes bronchodilation. Despite its potential therapeutic application in asthma, MediciNova announced in the mid-2000s that it would not pursue further clinical development of MN709, opting instead to prioritize other candidates in its pipeline, such as MN-166 (ibudilast).

Other names

MN-709MN709MN 709